A Phase I/II Study of TTI-621 Combined with Doxorubicin in People with Advanced Soft Tissue Sarcoma


Full Title

A Phase I/II Study of TTI-621 in Combination with Doxorubicin in Patients with Unresectable or Metastatic High-Grade Leiomyosarcoma


The purpose of this study is to assess the safety and effectiveness of the investigational drug TTI-621 when given in combination with the chemotherapy drug doxorubicin in people with inoperable or metastatic soft tissue sarcomas. TTI-621 helps the immune system find and kill cancer cells. Both medications are given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have inoperable or metastatic soft tissue sarcoma that has not been treated with more than one prior regimen of therapy.
  • Patients should recover from the serious side effects of previous treatments before receiving the study therapy.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Sujana Movva at 646-888-6787.





Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID